$700 Million Worth of Synthetic Bitcoin Is Circulating on the Ethereum Blockchain – Bitcoin News

According to onchain data, theres now 69,836 synthetic bitcoin tokens (over $700 million) circulating on the Ethereum blockchain. Out of the six synthetic bitcoin token projects, wrapped bitcoin (WBTC) commands the largest number of coins with over 63% and 44,622 WBTC.

Synthetic bitcoin (BTC) has grown massively in recent weeks and since news.Bitcoin.coms last report on the subject, there was 38,021 BTC circulating on the Ethereum chain.

Since then, that metric has jumped more than 83% as theres now 69,836 synthetic bitcoin tokens in the wild on September 7, 2020. Dune Analytics shows there are seven synthetic BTC projects but tBTC has zero coins minted, while the other six projects have between 45 BTC to over 40,000.

The top project minting the most synthetic BTC is the Wrapped Bitcoin (WBTC) protocol which commands roughly 44,622 BTC to-date or 63%. The Ren Protocols renBTC has over 23% of the aggregate total of synthetic BTC with 16,268 renBTC in circulation today.

The token hBTC has 4,810 and sBTC has a total of 2,918 at the time of publication. The two projects with the least amount of synthetic BTC is imBTC (1,173) and pBTC (45).

WBTC has gained a lot of traction, and on Monday reports detail that the organization Alameda Research obtained 70% of the WBTC minted in August. Alameda was cofounded by the FTX CEO Sam Bankman-Fried.

A great percentage of synthetic bitcoin is circulating among holders while the rest is used on platforms such as Compound, Balancer, Aave, and Uniswap.

Synthetic bitcoin trades take place on a few centralized exchanges like FTX and Binance has revealed listing WBTC this week. On decentralized exchange (dex) platforms, Synthetic bitcoin trades are happening on 0x, Bancor, Synthetix, Balance, Curve, and Uniswap.

Despite the massive growth and popularity, Ethereum cofounder Vitalik Buterin detailed that he has concerns about synthetic bitcoin projects.

I continue to be worried about the fact that these wrapped BTC bridges are trusted, Buterin wrote on August 16. I hope they can all *at least* move to a decently sized multi-sig, the developer added.

Following Buterins statements, the community discussed a research paper by the Wanchain project which claimed the Ren Protocol kept all the collateralized bitcoin in one address.

Paradoxically, we found that the Bitcoin address provided by renBTC that users transfer their real BTC to for locking has not changed since the first day it went online, the Wanchain report wrote.

Despite the trust issues, with 69,836 synthetic bitcoin tokens on the Ethereum blockchain, the ETH network continues to solidify itself as BTCs most dominant offchain solution.

What do you think about the $700 million worth of BTC circulating on the ETH chain in synthetic form? Let us know in the comments below.

Image Credits: Shutterstock, Pixabay, Wiki Commons, Dune Analytics,

Disclaimer: This article is for informational purposes only. It is not a direct offer or solicitation of an offer to buy or sell, or a recommendation or endorsement of any products, services, or companies. Bitcoin.com does not provide investment, tax, legal, or accounting advice. Neither the company nor the author is responsible, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on any content, goods or services mentioned in this article.

Read the original here:

$700 Million Worth of Synthetic Bitcoin Is Circulating on the Ethereum Blockchain - Bitcoin News

Exclusive mining could have negative implications for the Blockchain industry, say experts – Cointelegraph

Dr. Elias Strehle of the Blockchain Research Lab and Lennar Ante of the University of Hamburg recently warned that blockchain nodes engaging in exclusive mining have no incentive to forward new transactions to their peers.

They speculated that crypto miners may instead be incentivized to keep transactions confidential in the hope of being the only one who can earn the associated transaction fees.

Exclusive mining, which is a type of collusion between a transaction initiator and a single miner or pool, uses private channels to confirm transactions rather than broadcasting them on the public blockchain. It is only after they are recorded in a block that public blockchain that users become aware of such transactions.

The authors alleged that, since transaction costs represent regular income for miners, significantly increased transaction costs could be used to launder money by colluding with a miner.

As a result, criminals may see smaller blockchain networks as more suitable vehicles for money laundering or tax evasion via exclusive mining, the researchers noted.

Dr. Strehle and Ante identified two other possible motivations for engaging in exclusive mining: reducing transaction cost volatility and hiding unconfirmed transactions from the network to prevent frontrunning.

In June, Cointelegraph reported on a number of mysterious transactions that have stumped the wider community. Some suggest they could be examples of money laundering, or revenge from a disgruntled exchange employee.

Read more from the original source:

Exclusive mining could have negative implications for the Blockchain industry, say experts - Cointelegraph

Reimagining blockchain for healthcare solutions with the MAXathon – Health Europa

Blockchain technology company Maxonrow is hosting its first ever hackathon to help reimagine blockchain for applications in healthcare in response to the global challenges posed by the COVID-19 pandemic.

The MAXathon challenges are based on the Maxonrow SDK script, which the company used to build MedsLOCK. Created in tandem with Avantas Tech Accelerator, MedsLOCK is a blockchain-based control and communication ecosystem that provides real-time insights during pandemics.

During the COVID-19 outbreak, data is crucial to making informed decisions. At the same time, citizens are concerned about any incursion to privacy resulting from data collection initiatives.The MedsLOCK platform provides a single source of reliable, verifiable pandemic analytics to government agencies, health officials, and other stakeholders, and the core objective is to make COVID-19 data collection and exchange between stakeholders automated, transparent, and trusted with the help of distributed ledger technology.

Muhammad Salman Anjum, Avantas Managing Director, said: Privacy is a key issue during the current and future pandemics, and as such, blockchain platforms ensure that information is shared without compromising privacy. With MedsLOCK, we make sure we add trust to the data flow.

Participants in the MAXathon hackathon will have a chance to win a share of a 15,000 prize pool by building solutions for any of the five challenge categories.

The challenges categories are:

Physical Distancing Distancing measures are one of the most impactful ways to contain the spread of COVID-19. How can we use analytics in smarter solutions to help governments implement social or physical distancing measures?

Credential and Certificate Issuance Governments need a way of easily verifying if a patient has had COVID-19 and is virus-free. Help us build a solution that can help governments quickly retrieve verifiable data.

Welfare Businesses and citizens have become reliant on governments for welfare due to the restrictions imposed by the pandemic. Can we lower transaction costs by removing intermediaries and increasing transparency to welfare beneficiaries?

Virtualising the New Normal Are there any creative ways that blockchain can be used to navigate the need for physical distancing, creating new virtual paths to connect with one another?

UI/UX There are many data representations of the pandemic. How can we present a holistic, multi-dimensional dashboard with unique features?

Maxonrow has assembled a stellar team of judges and mentors for MAXathon, including Holger Schmidt, partner at PwCs strategy division, Nisa Amoils of VC firm Grasshopper Capital, along with representatives from Audi, Dash.org, and members of Maxonrow and Avantas Techs senior leadership.

There will also be 16 mentors working with participating teams, comprised of members of Maxonrows technical teams and leaders within the blockchain space.

The latter includes Amber Urquhart, Head of Business Development at quant trading firm TDX Strategies, Gabriel Dymowski, CEO at Doxychain, and a laureate of Forbes 25 under 25. Also participating in the mentorship team are Massimo Buoni, a UN global technology expert, and Steven Boylan, co-founder and CEO of Trt:Labs, a specialist digital transformation consultancy.


Reimagining blockchain for healthcare solutions with the MAXathon - Health Europa

All fintech companies will use blockchain within 10 years: Aussie government report – Cointelegraph

The Australian governments Senate Select Committee on Financial Technology and Regulatory Technology has released a draft report citing blockchain technology more than 50 times.

The report is in response to Australias first recession in 30 years as a result of COVID-19, which was confirmed in the June quarters negative growth announced on September 2.

The document makes numerous recommendations about how the nation can embrace technology and become globally competitive said committee head Senator Andrew Bragg. He added:

There are dozens of references to blockchain and distributed ledger technology and the report cites submissions to the committee that blockchain's potential is estimated at $175 billion annually within five years and $3 trillion by 2030. It quoted Piper Alderman partner Michael Bacina as saying blockchains use cases would grow exponentially across the financial and regulatory sectors:

The tax treatment of Initial Coin Offerings (ICOs) was addressed specifically with the recommendation that the regulatory framework around ICOs be developed to encourage blockchain development rather than inhibit it.

Power Ledgers co-founder and Executive Chairman Dr Jemma Green highlighted that more than $26 billion had been raised through ICOs, however Australia has captured less than one percent of this value. She explained that by implementing new tax regulations the country could capitalise on the opportunity, to capture a bigger piece of that $26 billion pie which would result in employment for employ tens of thousands of people.

Other use-cases for the technology cited include blockchain as a reporting and management tool for property data and investments, and within the credentialing sector.

The technology will also play an integral part in Australia's farming success through agricultural advancements, a sector set to grow to $100 billion by 2030 according to the National Farmers Federation. Senator Bragg said innovative technology is the only future for the farming sector.

The Committee will submit the final report in April 2021.

See more here:

All fintech companies will use blockchain within 10 years: Aussie government report - Cointelegraph

‘Decentralized Reddit’ enables users to secure Twitter on the blockchain – Cointelegraph

Reddit-inspired social aggregation platform Discussions.app announced its expansion to the Telos network on Sept. 3.

The first project to come out of the new collaboration will be a decentralized identity system, allowing users to record their accounts and contacts from Twitter and other social networks to the blockchain in the event of a block or ban.

In the social-media age, users spend years growing networks and followers on various platforms, although this work can be destroyed by the sometimes arbitrary-seeming decisions of the networks.

Discussions.app addresses this by allowing users to migrate across platforms without losing their valuable identities and connections. Telos chief architect Douglas Horn explained the problem:

It seems that every few days I see another unique voice de-platformed and the connections they invested years building pulled out from under them like a cheap rug especially in the crypto community. Discussions.app empowers individuals to secure their own social networks immune to the whims of Facebook, YouTube and Twitter.

As Cointelegraph reported, YouTube has arbitrarily banned (and then reinstated) a number of crypto-related channels over the past few months. In May, the platform even pulled the plug on our special livestream of the halving event.

In addition to digital identity management, Telos will provide Discussions.app with options for advanced governance and Ethereum Virtual Machines which can run Ethereum-compatible smart contracts with zero transaction fees.

Go here to read the rest:

'Decentralized Reddit' enables users to secure Twitter on the blockchain - Cointelegraph

Former Georgian PM: Blockchain is the steam engine of Industry 4.0 – Cointelegraph

Located at the intersection between Europe and Asia, Georgia is a small country with a big mission to drive blockchain adoption and education. In February 2017, the government of Georgia made a bold move by signing an agreement to use the Bitcoin blockchain to record land titles, making it the first national government to use blockchain for authenticating state operations.

Georgias innovation didnt stop there, rather continuing to grow as the country became a powerhouse for mining crypto. Then, in June 2019, the government of Georgia signed a memorandum of understanding with blockchain technology firm Input Output Hong Kong, or IOHK, to advance blockchain projects across government sectors, with a large focus on education.

Many of these innovations took place when Mamuka Bakhtadze served as the countrys prime minister, between June 2018 through September 2019. Cointelegraph had the pleasure of sitting down with Bakhtadze to learn more about his goals to drive blockchain innovation and education.

Rachel Wolfson: How did you start implementing blockchain and digital currencies into policy when you were Prime Minister of Georgia?

Mamuka Bakhtadze: This actually started before I became prime minister of Georgia. Georgia is the first country that introduced blockchain technology in public services. That happened a few years ago, when we partnered with the blockchain company Bitfury.

Our Ministry of Justice implemented Bitfurys blockchain to register and verify property transactions. This was the first time not only for Georgia, but for any state to implement blockchain in the public services sector.

RW: You recently spoke at the virtual Davos event this year about taking blockchain further; what can the future hold?

MB: Georgia is a very good example of the limitless opportunities associated with blockchain, especially within the public services sector. Currently, we are implementing a very important project in the education sector together with IOHK and Charles Hoskinson, who is a very good friend of Georgia. Together with the Ministry of Justice and Minister for Education, we are implementing the credentials verification project. The team is using a Cardano-backed blockchain for this.

When you want to make a transformation for your country, its very important to have a national idea that will consolidate the energy and effort required for it. In our opinion, this was education. In 2019, we initiated an education reform, and now, according to our legislation, it is mandatory for any government to invest 6% of GDP in education, which is around 25% of our budget.

So education is really a big element for Georgia. With this reform, we hope that we will be able to position Georgia as a hub for innovation, and blockchain plays a large role in this. The project that we are doing now with the Input Output team is very important from that perspective.

RW: Is Cardano and IOHK also setting up an education center in Georgia, where theyre teaching students about blockchain and then providing career opportunities?

MB: This is part of phase two of the plan. The first phase, as I have mentioned, is to finalize this project for credentials verification. The next phase will focus on the skill-building process for Georgians who would like to become part of this great initiative.

RW: Is the Georgian government also looking to implement blockchain solutions to revive tourism and travel that may have been impacted by COVID-19?

MB: Tourism is a very important industry for Georgia. Our population is less than 4 million people, and last year, we hosted more than 9 million visitors. So, tourism is really a very important industry for both the country and our economy.

I think blockchain can provide some very interesting solutions to this problem. Many countries are now trying to get data showing whether people have been tested for COVID-19. They also want information to show whether people have been living in so-called high-risk zones. At the same time, this is very sensitive data. Therefore, the security and safety measures of how to use this data is very important.

Blockchain can provide some interesting solutions for countries like Georgia who are so dependent on tourism. I know that there are some Asian countries that are working very intensively on these solutions. Georgia should also determine which technologies we will have to use to increase our visitors again. I think that blockchain would be the right answer to this question.

RW: What are your thoughts on Bitcoin and cryptocurrency in general, and how is this being applied in Georgia?

MB: Im a strong advocate for digital currencies and I have many strong arguments for being so supportive. Its a fact that we are living in the era of the Fourth Industrial Revolution. Digital currencies are an inevitable part of this era. At the same time, the lessons learned from the previous industrial revolutions are very interesting.

However, for countries like Georgia, the use of digital currencies an organic part of the fourth industrial revolution should become part of the transformation for both nations and their economies. Moreover, what we are learning now from the COVID-19 pandemic shows that the global economy needs digital currencies and cryptocurrency, which will make transactions safer and more efficient. Therefore, I think that its an inevitable process.

Of course, there are a lot of barriers, and I really do hope to see more of an open-minded approach from governments and regulators when it comes to digital currencies. But the bottom line is that all of us should understand that this move is inevitable. The countries who will be more supportive of digital currencies and cryptocurrencies will have a very significant competitive advantage in the 21st century. Georgia cannot afford to miss this opportunity.

RW: So would you say Georgia is crypto-friendly? Are digital assets going to be adopted in Georgia earlier than other places in the world?

MB: Im optimistic about this, and just to finalize the comparison I made with the first industrial revolution, I think another big part of this will be blockchain adoption. Blockchain will have the same impact as the steam engine had during the first industrial revolution. The first industrial revolution was powered by the steam engine and the fourth industrial revolution will be powered by blockchain. Thats really a game changer.

When it comes to regulations, politicians everywhere in the world and in Georgia should be more open-minded. Once again, the pandemic has shown us why. The global economy needs digital currencies now.

There are also a number of other initiatives. Of course, I would like to see Georgia as a frontrunner when it comes to blockchain and digital currencies.

Originally posted here:

Former Georgian PM: Blockchain is the steam engine of Industry 4.0 - Cointelegraph

How will decentralized blockchain technology evolve in the future? – Gary Skentelbery

So far, decentralized blockchain is best known as the technology that underpins Bitcoin and Ethereum. These public blockchain networks dominate the scene, both in terms of developer activity and cryptocurrencies traded.

Thats unsurprising considering the innovation both have enabled. A decade ago, Bitcoin provided a way for us to exchange value digitally and in a peer to peer manner with anyone else in the world. Roughly five years later, Ethereum enabled us to build sophisticated services around these value exchanges in the form of smart contract-enabled decentralized applications.

All of this innovation is understood by most people to revolve around decentralization. But what actually is decentralized blockchain?

This is an important question to be clear about before we look ahead to what the future holds and it is one that L3COS, a regulated blockchain-based operating system I recently discovered, does a good job of explaining.

It describes decentralized blockchain, as proposed by the creator of the Ethereum blockchain, Vitalik Buterin, as having three parts political decentralization, architectural decentralization and logical centralization.

Political decentralization means there is no regulating central authority, as is the case with Bitcoin. Architectural decentralization relates to infrastructure, with a network of distributed computers keeping the blockchain running together, so there is no single point of failure.

Logical centralization relates to the commonly agreed state of data, with all computers in a decentralized network sharing a single database.

As mentioned, these characteristics have been established norms for decentralized networks for many years now. However, as blockchain increases in significance with a wider variety of entities using the technology, the question of whether this will always be the case is an interesting thread thats worth pursuing.

Its worth stating that Bitcoin and Ethereum seem very unlikely to disappear entirely. Although they have not been adapted en masse, there have been signs in recent months that more and more of the traditional finance world is increasing its exposure to these key digital assets.

However, there is another important dynamic emerging in the world of blockchain that could have an important impact on the evolution of decentralized blockchain. Governments around the world are investigating the idea of issuing Central Bank Digital Currencies and using blockchain as the technology that underpins them. If they do so, they are unlikely to choose a blockchain that is politically decentralized in the way that Bitcoin and Ethereum are. This is noteworthy in relation to L3COS, which describes itself in the following terms:

Unlike most blockchains, L3COS is politically centralized. The operating system is designed to be regulated by the government.

It goes on to say that the system is based on three user levels, governments and members, businesses and their representatives, and society and individuals. Each level has its sublevels and permissions can be regulated on a personal basis, with the government ensuring every participant complies with these regulations.

The L3COS blockchain is architecturally decentralized but it is politically centralized. It claims to provide all the benefits of decentralization in terms of security, scalability, attack resistance and direct transactions between participants. However it also claims that regulation by government means the power of the technology will finally be recognised by businesses and individuals.

It seems clear that, now blockchain is really moving into the mainstream as a result of more and more governments and businesses using it, the technology will change from what we have today. In truth, the established decentralised networks may be extremely popular within the blockchain community but they are still just a tiny slice of the digital world.

These networks are unlikely to disappear as so many within the community have invested so much in them. But for new entrants who arent already affiliated with a particular network or community, they will be looking for the best solution for the needs. Who knows what this will mean for the future but theres no doubt government use of blockchain will be an increasingly important force and could have a dramatic effect on the evolution of decentralized blockchain.

See the original post:

How will decentralized blockchain technology evolve in the future? - Gary Skentelbery

How the Bitcoin Blockchain Is Being Used to Safeguard Nuclear Power Stations – CoinDesk – CoinDesk

Nuclearis, a manufacturer of precision mechanical components for the nuclear industry, is using the Bitcoin blockchain to verify the manufacturing blueprints of parts that make up nuclear power reactors.

Announced Tuesday, Nuclearis, which is headquartered in Buenos Aires, Argentina, and has offices in the U.S. and China, is using the Bitcoin-powered RSK blockchain as an immutable anchor, keeping tabs on critical documents. The firm has open-sourced the framework so other players in the nuclear industry can use it.

Its not the first time blockchain tech has been leveraged within the nuclear industry. Estonias Guardtime has been using its own version of DLT for some time to distribute data as a way to prevent cyberattacks on nuclear infrastructure. There have also been projects using blockchain to track the uranium fuel supply chain and also track what happens to nuclear waste.

Safety is everything when it comes to nuclear. The track and trace use case for manufacturing documents is important because there have been forgeries in the past, where antiquated nuclear reactors have opted for shortcuts to revamp equipment (a high-profile case of this sort went through the courts in France in 2016.)

Some 150 new reactors are set to be built over the next 30 years and the NuclearTech space is all about instilling trust within the operators of nuclear power plants, said Nuclearis CTO Sebastian Martinez.

Part of the problem is that there are many intermediaries in this supply chain and parts of it are still paper-based, said Martinez. We hash the manufacturing documents and upload to the blockchain at the point of creation of the steel part. Months or even years later, when we deliver the part, the power plant can check if everything digitally matches.

Nuclearis, which is working with Argentinas three power plants Atucha I, Atucha II and Embalse said the Argentine government and the countrys main operator of nuclear power plants, Nucleoelctrica Argentina, are looking to adopt its blockchain system.

The RSK blockchain developed with consultancy IOV Labs uses a process called merged mining to run a sidechain on the Bitcoin blockchain and harvest the hash power of the largest cryptocurrency.

The immutability and security that blockchain provides are of the most importance for the nuclear industry, IOV Labs CEO Diego Gutierrez Zaldivar said in a statement. We are very excited about Nuclearis solution in that industry and thrilled they have chosen RSK blockchain and RSK Infrastructure Framework (RIF) technologies for its development.

The RSK-based platform now in use is only for tracking the provenance of new parts, but there are lots of interesting use cases going forward around areas like decommissioning of parts, Nuclearis said.

If you replace something like a pump from a primary circuit that has been radioactive for the last 50 years, you have to decommission it, get it out of the reactor and dismantle it, said Martinez. Traceability of that stuff is very important so it doesnt turn up on some black market, or worse, finds its way into a dirty bomb.

See the article here:

How the Bitcoin Blockchain Is Being Used to Safeguard Nuclear Power Stations - CoinDesk - CoinDesk

Starbucks’ Deployment of a Blockchain Network May Show Restaurants the Way to Future Revenue Growth | – Restaurant Technology News

Soon it will no longer be a matter of just listing all your niche providers but being able to prove their legitimacy. This is not just for coffee, either. Think of every ingredient or item on display whose price could be enhanced through more granular traceability.By Larry Mogelonsky, Principal of Hotel Mogel Consulting Limited - 9.5.2020

Amidst all the headlines about COVID-19, you may have missed the coverage of what is potentially a gamechanger in the foodservice and retail industries. First announced over a year ago, Starbucks is now readying to deploy a blockchain network for end-to-end coffee bean traceability and greater product transparency, and this will soon influence what motivates customers to buy at your restaurant, sundry or store.

I love Starbucks. Not only are its products consistently great but, as a former advertising exec, the companys branding and marketing are perennially some of the best in the world. While undoubtedly you can find better coffee at independent cafs throughout the Mediterranean and Middle East, as a global franchisor Starbucks has revolutionized the way the world views and values coffee.

A while back, I wrote an article entitled, Fast Food Restaurants are Where Food Trends Go to Die, describing how, by the time you see a food trend being advertised by a major chain, its a mature concept and can no longer generate buzz for your own business. The underlying lesson here was to differentiate your product by not directly copying what dining patrons could find everywhere else. Starbucks, however, may be the exception to this principle in that it is the gold standard for premium coffee service and often the trendsetter for the industry rather than a laggard.

In essence, if you cant do better than Starbucks then why even bother? Now after its latest partnership with Microsoft to build a verifiable coffee production blockchain, Starbucks is raising the bar again where it goes, the competition will be forced to follow or inevitably lose market share.

As a start, blockchain is far more than just swanky cryptocurrencies like Bitcoin or Ethereum, and it would certainly help for you to cultivate a basic understanding of how the technology works. You wont need to become versed in distributed systems architecture, but you should know how a decentralized hyperledger with algorithmically linked or hashed and timestamped transactions can be used to authenticate a products origins. Plenty of resources exist online for you to peruse.

Now lets look at how the application of blockchain will evolve our current practices. Over a decade ago, hotels and restaurants started to embrace the concept of authentically local as a means of product differentiation and commanding higher prices. For eateries specifically, the locavore movement and reducing food miles became a way to simultaneously improve ingredient quality, support the region, take a stance against environmental degradation and justify upcharging customers to cover the increased costs. But how do you truly know if something is local besides taking a restaurant at its word?

Just as Burger King or Subway putting sriracha on the menu signaled the omnipresence and inert familiarity with this once-buzzy, Southeast Asian hot sauce, local has also lost much of its luster simply because everyone else is doing it. When you say that all your ingredients are locally sourced, it still adds value to the experience, but this messaging can no longer be assumed to be a primary motivator for customers to choose you over the competition. And at the luxury end, local in all things is now a firm expectation rather than a value-add.

Traceability, as powered by blockchain, is a strong contender to be the local for the new decade because it deepens the trust that guests will have with your products and it allows you, the purveyor, to source from niche producers around the world while also limiting the unethical interloping of middlemen. When it comes to marketing coffee, single origin has been a powerful trend for helping brand luxury products over the past five to ten years as people can choose between beans produced on an individual farm or small geographic territory in, say, Nicaragua versus from a Colombian finca, enriching the customer experience in the process. Blockchain adds an extra layer of security and authenticity to this model in that the beans are now exactly where they say they are from.

While setting up your own blockchain is likely an insurmountable task for any enterprise not approximating the size of Starbucks, perhaps in the near future there will be a consortium blockchain that you can subscribe to. Piggybacking on these networks may also entail many other operations besides supply chain management, notably facilitating secure contactless payments without the worry of chargeback disputes. In the meanwhile, whats important is that you grasp how this latest news will come to heighten guests demand for digital product transparency.

Soon it will no longer be a matter of just listing all your niche providers but being able to prove their legitimacy. This is not just for coffee, either. Think of every ingredient or item on display whose price could be enhanced through more granular traceability.

Do you believe that showing the exact cow pasture where a steak came from will allow you to charge more for that piece of meat? How about chocolate where cocoa is mostly produced in West Africa and yet those countries have largely failed to develop a homegrown direct-to-consumer industry because of too much exploitation by nefarious wholesalers? What if, instead of trumpeting your Belgian or Swiss chocolates, you vended products from an Ivory Coast startup that used blockchain to verify that its beans were wholly fair-trade or responsibly farmed.

While blockchain is a lofty goal these days for just about any hospitality organization, there are other old school ways you can deploy in the meantime to attain better product transparency, and you should consider them to help drive revenues for the decade ahead.

The worlds most published writer in hospitality,LarryMogelonsky is the principal of Hotel Mogel Consulting Limited, a Toronto-based consulting practice. His experience encompasses hotel properties around the world, both branded and independent, and ranging from luxury and boutique to select-service.Larryis also on several boards for companies focused on hotel technology. His work includes four books Are You an Ostrich or a Llama? (2012), Llamas Rule (2013), Hotel Llama (2015), The Llama is Inn (2017),The Hotel Mogel (2018)and More Hotel Mogel (2020). You can reachLarryatlarry@hotelmogel.comto discuss hotel business challenges or to book speaking engagements.

This article may not be reproduced without the expressed permission of the author.

Are you an industry thought leader with a point of view on restaurant technology that you would like to share with our readers? If so, we invite you toreview our editorial guidelines and submit your articlefor publishing consideration.

See original here:

Starbucks' Deployment of a Blockchain Network May Show Restaurants the Way to Future Revenue Growth | - Restaurant Technology News

Nanomedicine Market 2020 Global Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis And Forecast To 2026 |…

Nanomedicine Market

DataIntelo, 03092020: The research report on the Nanomedicine Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data and compared it with the changing market situations. The report covers all the necessary information required by new entrants as well as the existing players to gain deeper insight.

Furthermore, the statistical survey in the report focuses on product specifications, costs, production capacities, marketing channels, and market players. Upstream raw materials, downstream demand analysis, and a list of end-user industries have been studied systematically, along with the suppliers in this market. The product flow and distribution channel have also been presented in this research report.

Get a PDF Copy of the Sample Report for Free @ https://dataintelo.com/request-sample/?reportId=81345

The Major Manufacturers Covered in this Report:CombimatrixAblynxAbraxis BioscienceCelgeneMallinckrodtArrowhead ResearchGE HealthcareMerckPfizerNanosphereEpeius BiotechnologiesCytimmune SciencesNanospectra Biosciences

The Research Study Focuses on:

By Types:Quantum dotsNanoparticlesNanoshellsNanotubesNanodevices

By Applications:Segmentation encompasses oncologyInfectious diseasesCardiologyOrthopedicsOthers

By Regions:

To get this report at incredible Discounts, visit @ https://dataintelo.com/ask-for-discount/?reportId=81345

The Nanomedicine Market Report Consists of the Following Points:

Make an Inquiry of the Nanomedicine Market Report @ https://dataintelo.com/enquiry-before-buying/?reportId=81345

In conclusion, the Nanomedicine Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rate, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://dataintelo.com

Follow this link:

Nanomedicine Market 2020 Global Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis And Forecast To 2026 |...

Nanomedicine Market Segmentation By Qualitative And Quantitative Research Incorporating Impact Of Economic And Non-Economic Aspects By 2027 – Reports…

The report on the Global Nanomedicine Market provides a panoramic view of the current developments and progresses within the Nanomedicine market. The report further analyzes the impact of the novel COVID-19 pandemic on the Nanomedicine market and provides an accurate insight into the current and future market fluctuations. Factors likely to influence the growth of the market, current trends, opportunities, restraining factors, and business landscape are discussed in-depth in the market study.

The Nanomedicine market report further discusses the definitions, classifications, types, applications, market overview, manufacturing processes and costing, raw materials, among other key points. The report additionally provides SWOT analysis, investment feasibility, and investment return analysis.

Get a sample copy of the Nanomedicine market report @ https://www.reportsanddata.com/sample-enquiry-form/1048

The major players profiled in the global Nanomedicine market report include:

Arrowhead Pharmaceuticals Inc. AMAG Pharmaceuticals, Bio-Gate AG, Celgene Corporation, and Johnson & Johnson.

Market Segment by Regions:

Product Outlook (Revenue, USD Billion; 2017-2027)

Drug Delivery System Outlook (Revenue, USD Billion; 2017-2027)

Application Outlook (Revenue, USD Billion; 2017-2027)

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1048

Key Questions Answered in the Report:

Key takeaways from the Nanomedicine market report:

To read more about the Global Nanomedicine Market @ https://www.reportsanddata.com/report-detail/nanomedicine-market

Thank you for reading our report. For more information on customization, please reach out to us. Our team will ensure the report is tailored according to your needs.

Original post:

Nanomedicine Market Segmentation By Qualitative And Quantitative Research Incorporating Impact Of Economic And Non-Economic Aspects By 2027 - Reports...

Healthcare Nanotechnology (Nanomedicine) Market : Updates, Future Growth, Industry Analysis And Comprehensive Study On Key Players To 2020 2028 -…

Healthcare Nanotechnology (Nanomedicine) Market is analyzed with industry experts in mind to maximize return on investment by providing clear information needed for informed business decisions. This research will help both established and new entrants to identify and analyze market needs, market size and competition. It explains the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities and the threats faced by key players.

Sample Copy of This Report: https://www.quincemarketinsights.com/request-sample-64780?utm_source=st/ARSHAD

A 360 degree outline of the competitive scenario of the Global Healthcare Nanotechnology (Nanomedicine) Market is presented by Quince Market Insights. It has a massive data allied to the recent product and technological developments in the markets.

It has a wide-ranging analysis of the impact of these advancements on the markets future growth, wide-ranging analysis of these extensions on the markets future growth. The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.

Sanofi SA, Pfizer Inc., Celgene Corporation, Luminex Corporation, and Taiwan Liposome Company Ltd.

Reasons for buying this report:

By Application (Drug Delivery, Biomaterials, Active Implants, Diagnostic Imaging, Tissue Regeneration), By Disease (Cardiovascular Diseases, Oncological Diseases, Neurological Diseases, Orthopedic Diseases, Infectious Diseases and Other Diseases)

Healthcare Nanotechnology (Nanomedicine)

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-64780?utm_source=st/ARSHAD

A detailed outline of the Global Healthcare Nanotechnology (Nanomedicine) Market includes a comprehensive analysis of different verticals of businesses. North America, Latin America, Asia-Pacific, Africa, and Europe have been considered for the studies on the basis of several terminologies.

This is anticipated to drive the Global Healthcare Nanotechnology (Nanomedicine) Market over the forecast period. This research report covers the market landscape and its progress prospects in the near future. After studying key companies, the report focuses on the new entrants contributing to the growth of the market. Most companies in the Global Healthcare Nanotechnology (Nanomedicine) Market are currently adopting new technological trends in the market.

Finally, the researchers throw light on different ways to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the Global Healthcare Nanotechnology (Nanomedicine) Market. The feasibility of the new report is also measured in this research report.

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying-64780?utm_source=st/ARSHAD

Table of Contents:


QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.


Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 144 439 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Originally posted here:

Healthcare Nanotechnology (Nanomedicine) Market : Updates, Future Growth, Industry Analysis And Comprehensive Study On Key Players To 2020 2028 -...

NanoViricides is Developing Drugs Against SARS-CoV-2 with an Integrated Approach to Combat COVID-19, as Reported at The LD 500 Virtual Conference -…

SHELTON, CT / ACCESSWIRE / September 4, 2020 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today reported on the Presentation by Anil R. Diwan, Ph.D., its President and Executive Chairman, at the LD 500 investor conference yesterday, Thursday, September 3rd at 11:20 AM EDT.

Dr. Diwan presented the Company's rapid progress in developing a drug to attack the SARS-CoV-2 virus that causes COVID-19 spectrum of diseases.

He summarized the Company's progress since embarking into this endeavor with very limited resources since about January, 2020, and boot-strapping on its past work against coronaviruses. Dr. Diwan stated that the Company is close to declaring a clinical candidate for treating patients infected with SARS-CoV-2. The Company has previously reported that its development candidates have shown to be effective against multiple coronaviruses in the Company's own BSL2 Virology Lab, and have also shown to be highly effective in an animal study to combat infection by a related coronavirus that uses the same ACE2 receptor as does SARS-CoV-2.

Dr. Diwan stated that this broad-spectrum effectiveness against coronaviruses provides scientific reasoning that even as a field coronavirus strain mutates, our drug candidates would continue to remain effective, unlike antibodies and vaccines.

In addition, our current development candidates against COVID-19 have also been shown to be extremely safe in animal studies. Their effectiveness in cell culture and animal models has led us to believe that they are worthy of human clinical development.

Subsequently, the Company has completed CMC ("Chemistry, Manufacture, and Controls") studies that would be required for an IND ("Investigational New Drug) application to the U.S. FDA. The Company is also in the process of drafting sections of an IND for COVID-19 drug candidate. The Company is currently conducting studies to finalize its clinical candidate.

Dr. Diwan further stated the Company's intent of developing an integrated approach to combat SARS-CoV-2 that could potentially result in a cure for the virus. The virus lifecycle is a convolution of two parts: (a) re-infection of a host cell by external virus (after primary infection from outside the host body), and (b) replication (i.e. production of new virus particles) in infected cells and egress of the newly produced virus particles to feed back into the (a) re-infection cycle, completing the loop.

Dr. Diwan explained that if both parts of the virus lifecycle are blocked, then a virus infection would be cured, except in the case of latent viruses.

A nanoviricide® is uniquely capable of accomplishing this task of integrated attack against both the re-infection and replication mechanisms, as the Company has previously stated. The nanoviricide is already designed to block the re-infection cycle part. In addition, it can carry in its "belly", a payload that can block the replication cycle part.

NanoViricides has accelerated its anti-coronavirus program to develop a "second generation" nanoviricide against coronaviruses that is designed to block both re-infection and replication cycles, in addition to the current development of the "first generation" anti-coronavirus drug intended to block the re-infection cycle part. The Company accelerated these efforts due to both the severity of the pandemic, and the difficulty of curing the SARS-CoV-2 infection as exemplified by several recent unsuccessful or partially successful clinical studies.

In particular, the Company has successfully encapsulated remdesivir inside its current development drug candidates. The resulting drug, which is expected to be superior to remdesivir alone, as well as many other drugs, is already in pre-clinical testing, Dr. Diwan disclosed.

Remdesivir inhibits replication cycle by blocking the RNA polymerase activity essential for virus genome duplication. It is highly effective in cell culture studies against many viruses. However, its success in reducing viral load and pathology has been limited in human clinical studies. This is probably substantially due to the extensive metabolism that the drug is subjected to as soon as it enters the bloodstream.

Encapsulation into a nanoviricide is anticipated to protect remdesivir from this extensive metabolism and thus improve its clinical effect profile. Additionally, the nanoviricide itself is expected to block the re-infection cycle part of the virus lifecycle. Thus the Company believes that this novel integrated nanomedicine approach could produce a highly effective drug against coronaviruses, and against SARS-CoV-2 in particular, possibly on the way to a cure.

The Company develops its class of drugs, that we call nanoviricides®, using a platform technology. This approach enables rapid development of new drugs against a number of different viruses. A nanoviricide is a "biomimetic" - it is designed to "look like" the cell surface to the virus. The nanoviricide® technology enables direct attacks at multiple points on a virus particle. It is believed that such attacks would lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody.

Because of the worldwide urgency of the pandemic caused by the SARS-CoV-2 virus, we have focused all our efforts recently on taking a drug against SARS-CoV-2 into human clinical trials for treatment of patients with COVID-19. An effective drug could potentially allow full-fledged opening of normal activities, including schools, businesses, and economies all over the world.

Soon after it files an IND for a COVID-19 drug candidate, the Company intends to re-engage its NV-HHV-101 shingles drug candidate clinical trials program towards IND filing. The Company has put the shingles program on hold due to perceived difficulties in conducting proposed shingles clinical trials during the COVID-19 pandemic. The Company is near finalizing the selection of clinical trial sites and finalizing clinical trial protocols for the shingles IND filing.

The NV-HHV-101 drug candidate is expected to open up a billion dollar market for the shingles treatment space, and also lead to further development of drugs against other herpesviruses such as HSV-1 that causes "cold sores" and HSV-2 that causes genital herpes. The multiple indications enabled by the HerpeCide program drug candidates may potentially address a several billion dollar marketspace.

For additional information about NanoViricides, please visit the company's website at http://www.nanoviricides.com .

About NanoViricides NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. The Company is in the process of completing an IND application to the US FDA for this drug candidate. The Company cannot project an exact date for filing an IND because of its dependence on a number of external collaborators and consultants, the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus and Ebola/Marburg viruses. The Company has executed a Memorandum of Understanding with TheraCour that provides a limited license for research and development for drugs against human coronaviruses. The Company intends to obtain a full license and has begun the process for the same. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. CMC refers to "Chemistry, Manufacture, and Controls".

Contact: NanoViricides, Inc. info@nanoviricides.com

Public Relations Contact: MJ Clyburn TraDigital IR clyburn@tradigitalir.com

SOURCE: NanoViricides, Inc.

View source version on accesswire.com: https://www.accesswire.com/604794/NanoViricides-is-Developing-Drugs-Against-SARS-CoV-2-with-an-Integrated-Approach-to-Combat-COVID-19-as-Reported-at-The-LD-500-Virtual-Conference

Originally posted here:

NanoViricides is Developing Drugs Against SARS-CoV-2 with an Integrated Approach to Combat COVID-19, as Reported at The LD 500 Virtual Conference -...

Impressive Trends and Future Scope of Nanocapsules Market – StartupNG

Nanopharmacology is a new branch of pharmacology which deals with the application of nanotechnology in the field of nanomedicine. This is a potential step towards curing and prevention of disease by using molecular knowledge about human body and molecular tools. Nanopharmacology studies the interaction between nanoscale drugs and proteins such as DNA, RNA and cells & tissues. It also studies the interaction between physiological systems and traditional drugs at nanoscale level.

View Report : https://www.transparencymarketresearch.com/nanocapsules-market.html

Nanoparticles are solid colloidal particles that include both nanospheres and nanocapsules. Nanocapsule is any nanoparticles that consist of a shell and a space in which desired substances may be placed. It is made up of a nontoxic polymer. They are also known to be drug delivery agents in the size range of 10-1000 nm. These capsules are made up of molecules called as phospholipids such as liposomes. Now-a-days many other materials such as variety of polymers have been used to make nanocapsules by self assembly process. Polymeric capsules are studied extensively as particulate carriers in the medical and pharmaceutical fields as they act as good drug delivery systems as a result of their sustained and control release property and subcellular size.

The ultrafine size of nanocapsules itself is one of the useful function as the finer drug are suitable to be absorbed easily through biological systems. The special features and functions of nanoparticles include slow release: the capsules releases drugs molecules slower over a long period of time, quick release: the capsule shell breaks and comes in contact with a surface, specific release: the shell is designed to break open when a molecule receptor binds to a specific chemical and moisture release: the shell breaks down and releases drug in the presence of water among other features. The state of the art nanocapsulation medications include drugs deliver to specific locations within the body, cuts down on the amount of drug per dose and reduces the risk of side effects. The only limitation is that it is designed to target pre-determined areas.

Get Brochure of the Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5321

Cancer, neutraceuticals, ethyl alcohol absorption, food usage and self healing materials are the major applications of nanocapsules. Water soluble polymer shells are manufactured to deliver a protein known as apoptin into cancer cells. Neutraceuticals are substances which are placed into food to enhance nutrition. The smaller the nanocarrier, the better the delivery particles and solubility of neutraceuticals. Nanocapsulation in foods includes the changing of texture, coloring, flavoring and stability in shelf life. Nanocapsules are known to reduce damage that is caused by high loads for components in microelectronics, polymeric coatings and adhesives.

Growing pharmaceutical industry along with the rising demand for nanocapsules are expected to be the major factor driving the global nanocapsules industry. The growing demand from the end user industry is also expected to boost demand for nanocapsules in the near future.

Request For Covid19 Impact Analysis https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=5321

Asia Pacific is expected to be the largest consumer of nanocapsules due to growing pharmaceutical industries in the region. North America and Europe are also expected to boost demand for nanocapsules owing to the growing demand from the end-user industries for various applications.

Read our Case study at :https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

Some of the major players profiled for global nanocapsules market include: Capsulation, Sanzyme Ltd, PlasmaChem GmbH, NoCamels, Indian Instruments Manufacturing Company, Encap, Sintef, and Carlina Technologies among others.

More Trending Reports by Transparency Market Research 1.http://www.prnewswire.com/news-releases/increasing-number-of-accidents-and-injuries-to-drive-adoption-of-wound-closure-strips-market-valuation-to-rise-up-to-us446-3-mn-by-2027-end-finds-tmr-301019647.html


The rest is here:

Impressive Trends and Future Scope of Nanocapsules Market - StartupNG

Clene Nanomedicine, researching the use of gold atoms to slow ALS progression, nets $42.5M Series D – Endpoints News

A biopharma that uses gold to develop treatments for neurodegenerative diseases just got a little bit richer.

Clene Nanomedicine pulled in $42.5 million in a Series D financing round Wednesday, money which will go toward advancing its lead program through a Phase III platform trial in ALS and support Phase II trials in MS, Parkinsons disease and ALS. CEO Rob Etherington said that by the end of 2021, Clene will know whether or not the candidate, called CNM-Au8, will prove effective.

It will take us to the end of all these clinical endpoints, Etherington told Endpoints News. The exciting thing for us is that one asset could potentially be indicated to improve neurological function in MS, as well as ALS, and [though] Parkinsons is the slower program, this money is going to help us launch more completely that program.

CNM-Au8 is a liquid suspension of gold nanocrystals that catalyze intracellular biological reactions. Such catalyzation can lead to improvement in nerve cell survival, function, and communication. Chemically, the clean surfaces of the nanocrystals help normalize ATP production in cells, which is lacking in serious neurological diseases like ALS, CMO Robert Glanzman said.

Were providing bioenergy support to cells, Glanzman said. Theres a reason why we tend to get neurodegenerative diseases as we get older, and that is because as we age, theres a linear loss of bioenergetic capacity within neurons and what were doing is actually providing these neurons and other cells with free energy, essentially.

In terms of visible symptoms, Glanzman added that patients taking CNM-Au8 will see better strength, muscle mass and be able to speak, breathe and swallow more easily over a longer period of time.

Clenes Phase III study comes as it was selected to participate in the first-ever platform trial for ALS, which enrolled its first patients earlier this month. The trial compares three separate treatments for the disease, with UCBs zilucoplan and Biohavens verdiperstat joining CNM-Au8 at Harvard-backed Massachusetts General Hospital in testing 480 total patients.

Though delayed from a March start due to the Covid-19 pandemic, the platform trial aims to expedite the development of therapies for a disease that advances rapidly and that has few effective treatment options. Only riluzole, also known as Rilutek and OKed in 1995, shows any measurable effect on ALS patients, Etherington said.

Riluzole, which functionally is really the only drug that most people with ALS use, was originally approved to delay the need for tracheostomies to encourage breathing for an extra couple months, Etherington said. But it has a very modest effect generally. It is the standard of care, however, because its the only really markedly relevant drug thats been approved for ALS in this country. Theres a few others but most of them do very little.

Clene has two other programs in the pipeline, though neither have reached the clinic just yet. The first is a topical gel containing silver and zinc ions, with researchers looking at burn treatment, accelerated wound-healing and as an anti-infective. Theres also a gold-platinum therapeutic being studied for use in oncology, which is still in the initial in vitro stage.

The bottom line for Clene though is that finding a treatment option for the extremely difficult ALS indication becomes closer to reality, with a potentially huge impact on the field.

The way you and I move and can grasp things and can talk, all this fine motor movement we take for granted, Etherington said. An ALS patient loses these and this is exactly what we are studying.

Read more from the original source:

Clene Nanomedicine, researching the use of gold atoms to slow ALS progression, nets $42.5M Series D - Endpoints News

Amorphous Soft Magnetic Materials Market to Reach USD 728.5 Million by 2027; Need to Blend Amorphous & Nano-crystalline Alloys will Favor Growth,…

Pune, Sept. 02, 2020 (GLOBE NEWSWIRE) -- The global amorphous soft magnetic materials market is set to gain traction from the increasing research activities to develop new fabrication methods. Several researchers are striving to blend amorphous and nano-crystalline alloys for improving ductility & thermal stability. Fortune Business Insights presents this information in a new study, titled, Amorphous Soft Magnetic Materials Market Size, Share & COVID-19 Impact Analysis, By Application (Electronic Article Surveillance, Flexible Antenna, Magnetic Sensors, Magnetic Shielding, Transformers, and Others), and Regional Forecast, 2020-2027. The study further mentions that the market size was USD 522.4 million in 2019 and is projected to reach USD 728.5 million by 2027, exhibiting a CAGR of 4.7% during the forecast period.

COVID-19: High Demand for Medical Equipment to Affect Market Positively

The COVID-19 pandemic has caused severe economic losses for a wide range of industries. But, it has affected the field of amorphous soft magnetic materials positively. The main reason behind this is the high demand for medical equipment, such as ventilators, MRI machines, and CT-scanners worldwide. In March 2020, the Society of Critical Care Medicine mentioned that approximately 9, 60,000 patients would require ventilators amid this global pandemic in the U.S. alone. Hence, the need for global amorphous soft magnetic materials would grow rapidly as they help in manufacturing high-quality equipment.

Our reports are specially created to help you better understand the effects of the pandemic on every market. You can select the best available strategy and surge business confidence once again.

Get Sample PDF Brochure with Impact of COVID19:


This Report Answers the Following Questions:

Drivers & Restraints

High Demand for Amorphous Alloys to Accelerate Growth

Amorphous alloys mainly contain cobalt, nickel, and iron with silicon or phosphorus, carbon, and boron. Industrial consumers are nowadays trying to reduce operating cost, save energy, and operate efficiently. Hence, they are looking for amorphous alloys which are helping them to fulfil their requirements. Apart from that, they have numerous significant properties, such as good mechanical strength and low coercive field. These factors are set to boost the amorphous soft magnetic materials market growth throughout the forthcoming years. However, the availability of several substitute soft magnetic materials may hamper growth.


Transformer Segment to Lead Backed by Presence of Amorphous Alloys in Magnetic Core

Based on application, the market is segregated into transformers, magnetic shielding, magnetic sensors, flexible antenna, electronic article surveillance, and others. Out of these, the transformers segment held 55.9% in terms of amorphous soft magnetic materials market share in 2019. This segment would lead the market in the near future as amorphous alloys are extensively used to develop the magnetic core of the transformers. This, in turn, provides improved efficiency and reduces the overall weight of the transformer.

Inquire Before Purchasing this Report:


Regional Analysis

Asia Pacific to Dominate Stoked by Rising Development of Transformers in China

Regionally, Asia Pacific generated USD 286.1 million in terms of revenue in 2019. This growth is attributable to the major contributions of China. It is considered to be one of the largest manufacturers of amorphous metal transformers, thereby resulting in the surging demand for amorphous soft magnetic materials. Apart from that, the rising usage of electric vehicles (EVs) in this country is set to augment the market growth in Asia Pacific. Europe, on the other hand, is expected to remain in the second position stoked by the presence of a well-established electronics industry in Germany.

List of the Leading Companies Profiled in the Global Amorphous Soft Magnetic Materials Market are:

Competitive Landscape

Key Players Aim to Launch New Amorphous Soft Magnetic Materials to Intensify Competition

The market consists of a wide range of companies functioning from across the globe. They are trying to strengthen their positions and overtake their rivals by introducing state-of-the-art products in the market.

Below are two of the latest industry developments:

Browse Detailed Overview of This Research with Table of Content:


Detailed Table of Content:

TOC Continued!!!

Get your Customized Research Report:


Have a Look at Related Research Insights:

Permanent Magnet Market Size, Share & Industry Analysis, By Type (Neodymium Iron Boron (NdFeB), Ferrite, Samarium Cobalt (SmCo), Aluminum Nickel Cobalt (Alnico), and Others), By Application (Consumer Electronics, Automotive, General Industrial, Medical Devices, Energy, and Others), and Regional Forecast, 2019-2026

Copper Magnet Wire Market Size, Share and Global Trend By Type (Round, Rectangular), By Application (Motors, Transformers, HVAC Systems, Electronic Appliances, Others), By End-User (Residential, Commercial, Industrial) and Geography Forecast till 2026

Abrasives Market Size, Share & COVID-19 Impact Analysis, By Material (Natural and Synthetic), By Product (Bonded, Coated, and Super), By Application (Automotive, Electrical & Electronics, Metal Fabrication, Machinery, and Others), and Regional Forecast, 2020-2027

Pulp and Paper Market Size, Share & COVID-19 Impact Analysis, By Category (Wrapping & Packaging, Printing & Writing, Sanitary, News Print and Others), and Regional Forecast, 2020-2027

Piezoelectric Materials Market Size, Share & Industry Analysis, By Type (Piezoceramics [Lead Zirconate Titanate and Lead-free Ceramics], Piezopolymers, Piezocomposites), By Application (Actuators, Motors, Transducers, Sensors, SONAR, Generators & Transformers, Acoustic Devices, Resonators), By End-Use Industry (Automotive, Healthcare, IT & Telecom, Consumer Goods, Aerospace & Defense), and Regional Forecast, 2020-2027

Aerospace & Defense Materials Market Size, Share & Industry Analysis, By Material (Titanium Alloys, Aluminum Alloys, Composites, Super Alloys, Steel and Others), By Aircraft (Commercial, Military, Business & General Aviation and Others) and Regional Forecast, 2020-2027

Permanent Magnet Moving Coil Instrument Market Size, Share & Industry Analysis, By Magnet Material (Aluminium-Nickel-Cobalt (Alnico), Strontium-Iron, Neodymium-Iron-Boron, Samarium-Cobalt, Others), By Instrument (Ammeters, Voltmeters, Galvanometer, Ohmmeter, Others), By Application (Commercial, Educational, Industrial, Mobility, Others) and Regional Forecast, 2019-2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights, we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd.308, Supreme Headquarters,Survey No. 36, Baner,Pune-Bangalore Highway,Pune- 411045, Maharashtra,India.Phone:US: +1-424-253-0390UK: +44-2071-939123APAC: +91-744-740-1245Email:sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn|Twitter|Blogs

Read Press Release:


See original here:

Amorphous Soft Magnetic Materials Market to Reach USD 728.5 Million by 2027; Need to Blend Amorphous & Nano-crystalline Alloys will Favor Growth,...

5 Recent Tech Innovations Disrupting the Medical and Healthcare Industry – HealthTechZone

Technology is at our fingertips. Think of all the health monitors or wearable fitness trackers that people are using today. Virtual healthcare practices have changed our attitude towards the medical and healthcare industry. While there are loyalists as well as dissenters who rue the lack of personal connection with the doctor and quality care, tech innovations are breaking barriers meanwhile.

Technology in Healthcare

It could be as simple as information sharing between doctors and patients, or something as profound as robotic aid in a high-risk surgery. Better still, make it a remote surgery where the patient and doctor are separated by miles in between them! Clearly, recent tech advancements are disrupting the medical and healthcare industry with its dynamic applications.

It started with the online consultations and took off from there.

Telemedicine or virtual consultations are a thing of the past now. Even when they started, the dramatic impact it had on traditional healthcare roles has changed our collective attitude towards the industry. As these technologies develop further, more applications for professionals and patients stand to promote the overall wellness. Today, apps on the phone track our exercise and calorie intake, check obesity development, and monitor heart health.

Here are 5 recent tech innovations that have disrupted the industry for the long haul:

1. Virtual Reality or AR/MR/VR in Healthcare

Both medical professionals and patients stand to benefit from the multi-sensory, immersive experience that VR provides.

Think of realistic and low-risk simulated environment for training surgeons. On the other hand, in the arena of pain management or mental health, immersion in virtual worlds can produce better results. VRs therapeutic potential and rehabilitation chances in acute pain and anxiety disorder cases are far-reaching.

2. Nanomedicine

This is the stuff of sci-fi genres. Nanotechnology and nanodevices are arming the healthcare industry with control on the molecular level. Nanopharmaceuticals are aiming at smaller drugs and more precise delivery systems. For instance, delivering chemotherapy to targeted tumours rather than poisoning the whole body.

3. 3D Printing

Creating medical tools from buildable materials ranging from plastic to stem-cells, 3D printing has revolutionised the medical industry. Aided by the custom-friendly aspect of 3D printing, organ transplants and tissue repair, prosthetics and braces, even layered stem-cell organoids are possible today. Faster prototypes at a fraction of the traditional cost is a huge leg-up in the healthcare scene. The most dazzling innovation through this method is the poly-pill that holds several drugs for multiple illnesses with different release times!

4. Internet of Medical Things or IoT

Connected devices, cloud-computing, and the internet have allowed a larger the exchange of data, convenience, and automation. The IoT is significantly changing how healthcare professionals can manage patient records, control inventory, monitor and provide preventative care. In a way, this could be the most significant disruptive technology as a lot of other tech advancements have been possible only through this.

5. Precision Medicine

Diagnosis, treatment, and preventive care based on an individuals environment, lifestyle, and genetic makeup is a big shift from the all-purpose generic approach. Precision medicine is suggested based on diagnostic and molecular genetic testing processes such as genome sequencing and DNA mutation investigations. This will revolutionise preventive measures reducing treatment time and expenditure as well as healthcare requirement.

As healthcare and technological advancements grow together, the industry becomes more optimised providing quality care. It is evident in the cosmetic health industry where non-surgical procedures have advanced significantly. You can get Botox in Perth with breakthrough serums and great aftercare with minimal or no recovery time.

In fact, tech innovations have disrupted the healthcare industry so significantly, it is impossible to see it survive without them.

Read more:

5 Recent Tech Innovations Disrupting the Medical and Healthcare Industry - HealthTechZone

Mohali INST scientists develop new nano-particle-based treatment for kala azar – The Tribune India

Vijay Mohan

Tribune News Service

Chandigarh, August 21

Patients affected by kala azar, one of the most neglected tropical diseases, may soon find relief in an oral medicine from India. Scientists from the Institute of Nano Science and Technology (INST), Mohali, have developed a nano-medicine by combining different compounds for combating the disease.

Scientifically called Visceral Leishmaniasis (VL), kala azar is a disease in which a parasite migrates to the internal organs such as the liver, spleen or bone marrow and, if left untreated, will almost always result in the death of the host, according to medical literature.

It is a major health problem in India with an estimated 1.5 lakh new cases per year and also a serious concern in many other developing countries. About 95 per cent VL cases in the world are reported from Bangladesh, Brazil, China, Ethiopia, India, Kenya, Nepal, Somalia, South Sudan, and Sudan.

While general symptoms of VL include fever, weight loss, fatigue, anaemia and substantial swelling of the liver and spleen, infliction of the disease can also be asymptomatic in some cases. Since it is spread by insects and parasites, VL is a community problem and requires individual and society participation in its control.

In their project, supported by the Department of Science and Technology - Science and Engineering Research Boards (DST-SERB) Early Career Research Award, INST scientists have developed an oral nano-medicine with the help of surface-modified solid lipid nano-particles-based combinational system for treating the disease.

According to the INST team, till date, there is no study reported where a combination of two anti-leishmanial drugs has been delivered through nano-modification as a potential therapeutic strategy against VL. This work suggests the superiority of the combination prepared by them as a promising approach towards the oral delivery of anti-leishmanial drugs, the Ministry of Science and Technology said on Friday.

The INST team was led by Dr Shyam Lal. Anti-leishmanial drugs Amphotericin-B and Paromomycin were encapsulated in solid lipid nano-particles and further modified with a Hydroxypropyl-Cyclodextrin compound. The nano-particle combinatorial drug delivery system developed by them enhanced the efficacy of the formulation by reducing intracellular amastigote growth in cells without causing any significant toxic side-effects.

This study by the INST team, published in the journals Scientific Reports and Materials Science and Engineering C, may lead to product and process patents, enhancing indigenous capability for developing innovative therapy against neglected diseases. The usage of lower therapeutic dose of the purified drugs through nano-modifications will greatly help in reducing toxicity, which has been a major hindrance in the existing conventional treatment, when administered orally.

Excerpt from:

Mohali INST scientists develop new nano-particle-based treatment for kala azar - The Tribune India

Book Review: What Can India’s Embrace of Nanotech Tell Us About India’s Science? – The Wire Science

A glass nanoparticle suspended in an optical cavity. Photo: uclmaps/Flickr, CC BY 2.0.

Nanotechnology may not be a familiar term to many although nanotechnology-based products are available in the market and many consumers use them. Thanks to Nano Mission, an initiative funded by the Government of India through the Department of Science and Technology from May 2007, India has made great strides in nanosciences and engineering.

In this regard, Nanoscale, a new book by Pankaj Sekhsaria, a policy researcher at the Centre for Technology Alternatives for Rural Areas, IIT Bombay, doesnt eulogise the technology and its achievements nor does it criticise them and their deployment and risks.

Instead, Sekhsaria takes an atypical tack to set out what is possible, offering us new ways to conceive of and evaluate research. Through four case studies, he attempts to understand the links between science, technology and society at different sites and at different scales as if to ensure we are aware of what all is possible before we embark on our respective critical journeys. They are:

1. Developing a cutting-edge microscope at a university in Pune, despite severe constraints

2. Using nanotechnology to validate some components of a traditional Ayurvedic preparation

3. The failure of an innovative product a nano-silver-coated ceramic candle used to purify water in households

4. Nanotechnology-based treatment protocols for retinoblastoma, a cancer that affects children

The first case study concerns the construction of a scanning tunnelling microscope by C.V. Dharmadhikari at the University of Pune, using a variety of materials, including nanoparticles. Sekhsaria describes how Dharmadhikari built this sophisticated device from scratch, indigenously, and which he and his team now use for their research.

With this in mind, Sekhsaria invokes the concept of jugaad and the culture of innovation in laboratories around India. However, Eric von Hippels user innovation theory offers a better explanation: that more innovation is driven by intermediate or end users, at the site of consumption, which is then integrated by suppliers. In this case, Dharmadhikari is both a user and an innovator: he first developed the instrument and then, in the course of using it, continued to make minor modifications to better suit his and his peers purposes.

In fact, this would be true of most scientific instruments which are constantly attended to by a community of user-innovators of PhD students, postdoctoral researchers and investigators. As a result, in an ecosystem where resources are scarce and grants and funds are constantly shadowed by uncertainty, such DIY endeavours contribute more innovation and help adapt sophisticated technologies for more local conditions including nanotechnology.

Sekhsaria subsequently describes the fate of Dharmadhikari et als scanning tunnelling microscope, and compares it to that of similar innovations elsewhere in India. However, he stops short of discussing the range, utility and novelty of such instruments and how they have enabled Indian scientists to pursue science despite their constraints. Nor is there mention of how common such solutions are common across disciplines and institutions. Of course, user innovation can occur even when new instruments are acquired but if building instruments from scratch is very widely practised, it deserves a fuller study, as an important dimension of doing science in India.

The second case study concerns the use of nanotechnological tools to validate the components of a traditional Ayurvedic preparation, called bhasmas, and related work at the Centre for Nanobioscience, Agharkar Research Institute, Pune. Using the studies of Rinku D. Umrani, Sekhsaria highlights how the dialog between modern science (nanotechnology) and traditional medicine (Ayurveda) is necessary, although there are skeptics on both sides.

While the usefulness of traditional medicine is well known and accepted, it is often debunked as unscientific or considered to be scientifically unprovable. But a dialog could help better understand each system from the other systems perspective, paving the way for potentially fruitful collaborations.

With the specific example of bhasmas, Sekhsaria focuses the discussion onto the challenge of checking if Ayurveda can provide an alternative way to manage diabetes. Umranis work suggests that the mechanisms of action of some Ayurvedic preparations, including bhasmas, involve reactions involving nanoparticles. But instead of limiting himself to a yes/no answer, Sekhsaria argues that validation is necessary but a dialog as equals is more important to facilitate further research that, by extension, the introduction of radical new technologies brings with it radical new opportunities to improve the way we organise and conduct research.

Also read: Why Elon Musk Isnt Right About Nanotechnology Being BS

The third case study highlights how an innovation perceived to be locally useful to provide good quality drinking water at the household level using nanosilver-coated candles failed in the market. Researchers at the International Advanced Research Centre for Powder Metallurgy and New Materials (ARCI), Hyderabad, had developed these devices, essentially ceramic candles coated with nanoparticles of silver that could filter out some bacterial species from water.

But for the fact that they were simple to use, required less maintenance and were locally produced, they flopped at the market because they rested on the products uniqueness instead of adjusting for consumer behaviour and aspirations. The ceramic candle platform itself was becoming obsolete as a water purification technology, and newer entrants, ranging from advanced filters to ultraviolet and reverse-osmosis systems, all of which trapped more than bacteria, heightened buyers expectations.

Nonetheless, the candles were still useful, especially in low-cost settings. So Sekhsaria contends that such products shouldnt have been left at the mercy of market forces and that the government should have stepped in with subsidies. In fact, he challenges the idea that nanosilver-coated candles are obsolete per se, and argues that obsolescence is linked to infinite demands and consumption and that ARCI might have had more success if it had involved end-users during the product development process. According to him, there is also scope to recalibrate, renegotiate and revive the product, especially if were willing to learn from our mistakes.

The fourth case study is on treating retinoblastoma in female children. While nanotechnology is expected to offer better solutions like using gold-based nanoparticles to destroy cancer cells in a photothermal process the grim reality is that in some cases, parents prefer not to treat the child and let her die. This is because when children afflicted with retinoblastoma are not treated on time, they may lose eyesight and sometimes even their lives. In this regard, Sekhsaria spotlights how clinicians often talk to these childrens parents as if they are activists, and attempt to educate parents.

There is hardly any categorised data on retinoblastoma in India and how different sections of society have responded to it. It is true that technology is no panacea and the social complexities have to be taken into account but the complexity cant be reduced to that of only discrimination.

Sekhsaria discusses how girls and women are discriminated against, and how some parents choose to ignore new technologies that offer better treatment in favour of letting them die. However, his foundation is almost entirely anecdotal, based on discussions he had in two institutions in Hyderabad and Chennai. His analysis would have been enriched by including examples from more institutions, even if only in these cities, and could have fortified Sekhsarias arguments.

As such, the reader is unable to generalise from his examples as to the fraction of parents in the country who decide thus and why, nor whether the parents of male children behave the same way. Moreover, Sekhsaria discusses only those cases where parents didnt treat the child even if they had the option to do so, or accessed treatment when the retinoblastoma had entered the later stages.

Instead, the discussion could have covered the class and access to treatment dimensions. Unless we know how different sections of society respond to all the options available to them, the books view remains one-dimensional and unable to help us understand the technology-society interface. Nanotechnological solutions are not yet in vogue and are years away from widespread adoption. And even if nanotechnology has to have a positive impact, its success depends on the solutions affordability, accessibility and the decisions of parents who need to decide what is best for their children and themselves.

In fact, overall, Nanoscale often doesnt go far enough to flesh out the stories it uses to make its point about the unique prevalence of nanotechnologies across four very different slices of society, as if the book is attempting to anticipate the nanos outsized impact on society, and even social relations, in future.

Currently, India publishes the third-highest number of research papers on nanotechnology in the world. Nanotechnologies themselves have applications in sectors ranging from agriculture to textiles, from medicine to construction materials. For example, nano-fertilisers can help increase the efficiency with which plants use nutrients in the soil and help reduce nutrient run-off. Researchers have also used precepts of nanotechnology to improve hydrogen-based renewable energy technologies.

Also read: Why India Needs Nanotechnology Regulation Before it is Too Late

In this regard, Nanoscale provides a new perspective on nanotechnology in India and asks important questions about the corresponding science, technology and policies of innovation. Sekhsaria also successfully subverts conventional wisdom on innovation and attempts to link jugaad with sophistication, calls for dialog between modern science and traditional medicine, and highlights how the market can destroy innovations even as it patronises more expensive technology.

As such, Sekhsarias reluctance to pronounce verdicts works to the books advantage because, by highlighting the gap between traditional ideas of innovation in laboratories and the ground reality, he is able to contend that we can utilise nanotechnologies to a fuller extent by applying them to areas where there is a contest of paradigms or worldviews.

Krishna Ravi Srinivas works at Research and Information Systems for Developing Countries, a policy research think-tank. The views expressed here are the authors own.

Read more:

Book Review: What Can India's Embrace of Nanotech Tell Us About India's Science? - The Wire Science

Healthcare Nanotechnology (Nanomedicine) Market Analysis, Key Players, Industry Segments And Forecast To 2026 – The News Brok

The Healthcare Nanotechnology (Nanomedicine) market report 2020-2026 provides in-depth study of market competitive situation, product scope, market overview, opportunities, driving force and market risks. Profile the Top Key Players of Healthcare Nanotechnology (Nanomedicine), with sales, revenue and global market share of Healthcare Nanotechnology (Nanomedicine) are analyzed emphatically by landscape contrast and speak to info. Upstream raw materials and instrumentation and downstream demand analysis is additionally administrated. The Healthcare Nanotechnology (Nanomedicine) market business development trends and selling channels square measure analyzed. From a global perspective, It also represents overall industry size by analyzing qualitative insights and historical data.

Key players operating in the global Healthcare Nanotechnology (Nanomedicine) market includes : Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith&Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International, and among others.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Healthcare Nanotechnology (Nanomedicine) Market @https://www.researchmoz.us/enquiry.php?type=S&repid2041239

Key Target Audience of the Healthcare Nanotechnology (Nanomedicine) market:

Scope of Healthcare Nanotechnology (Nanomedicine) Market:

The global Healthcare Nanotechnology (Nanomedicine) market is valued at million US$ in 2019 and will reach million US$ by the end of 2026, growing at a CAGR of during 2020-2026. The objectives of this study are to define, segment, and project the size of the Healthcare Nanotechnology (Nanomedicine) market based on company, product type, application and key regions.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Healthcare Nanotechnology (Nanomedicine) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Healthcare Nanotechnology (Nanomedicine) market.

The report offers an exhaustive geographical analysis of the global Healthcare Nanotechnology (Nanomedicine) market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The end users/applications and product categories analysis:

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate foreach application.

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, market share and growth rate ofeach type.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid2041239

Healthcare Nanotechnology (Nanomedicine) Market The Regional analysis covers:

Key Findings & Data Available in Healthcare Nanotechnology (Nanomedicine) Market Report:

And Many More.

Get Discount on Healthcare Nanotechnology (Nanomedicine) Market Report :https://www.researchmoz.us/enquiry.php?type=D&repid2041239

Contact Us:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email: [emailprotected]Follow us on LinkedIn @ http://bit.ly/2RtaFUo

Follow me on : https://marketnews-24.blogspot.com/

Read more here:

Healthcare Nanotechnology (Nanomedicine) Market Analysis, Key Players, Industry Segments And Forecast To 2026 - The News Brok